(VIANEWS) – Pioneer Natural Resources (PXD), Corcept Therapeutics Incorporated (CORT), Ambac Financial Group (AMBC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Pioneer Natural Resources (PXD)
43.4% sales growth and 20.99% return on equity
Pioneer Natural Resources Company operates as an independent oil and gas exploration and production company in the United States. The company explores for, develops, and produces oil, natural gas liquids (NGLs), and gas. It has operations in the Midland Basin in West Texas. The company was founded in 1997 and is headquartered in Irving, Texas. As of May 3, 2024, Pioneer Natural Resources Company operates as a subsidiary of Exxon Mobil Corporation.
Earnings Per Share
As for profitability, Pioneer Natural Resources has a trailing twelve months EPS of $20.22.
PE Ratio
Pioneer Natural Resources has a trailing twelve months price to earnings ratio of 13.39. Meaning, the purchaser of the share is investing $13.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.99%.
Sales Growth
Pioneer Natural Resources’s sales growth is 30.2% for the ongoing quarter and 43.4% for the next.
2. Corcept Therapeutics Incorporated (CORT)
35.4% sales growth and 21.91% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $1.05.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 26.5. Meaning, the purchaser of the share is investing $26.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.91%.
Moving Average
Corcept Therapeutics Incorporated’s value is way higher than its 50-day moving average of $24.27 and above its 200-day moving average of $26.65.
Revenue Growth
Year-on-year quarterly revenue growth grew by 39%, now sitting on 523.53M for the twelve trailing months.
Yearly Top and Bottom Value
Corcept Therapeutics Incorporated’s stock is valued at $27.83 at 01:22 EST, way under its 52-week high of $34.28 and way above its 52-week low of $20.84.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 673900 which is 37.91% below its average volume of 1085370.
3. Ambac Financial Group (AMBC)
34.1% sales growth and 4.2% return on equity
Ambac Financial Group, Inc., a financial services holding company, provides financial guarantees in the United States, the United Kingdom, Italy, Austria, Australia, France, and Internationally. It offers financial guarantee insurance policies; and credit derivative contracts and interest rate derivative transactions. The company was incorporated in 1991 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Ambac Financial Group has a trailing twelve months EPS of $1.34.
PE Ratio
Ambac Financial Group has a trailing twelve months price to earnings ratio of 13.42. Meaning, the purchaser of the share is investing $13.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.2%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 100% and a drop 91% for the next.
4. Walker & Dunlop (WD)
10.5% sales growth and 5.01% return on equity
Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products and services for owners and developers of real estate in the United States. The company offers first mortgage, second trust, supplemental, construction, mezzanine, preferred equity, and small-balance loans. It also provides finance for multifamily, manufactured housing communities, student housing, affordable housing, and senior housing properties under the Fannie Mae's DUS program; and construction and permanent loans to developers and owners of multifamily housing, affordable housing, senior housing, and healthcare facilities. In addition, the company acts as a debt broker to work with life insurance companies, banks, and other institutional lenders to find debt and/or equity solution for the borrowers' needs; and offers property sales brokerage services to owners and developers of multifamily properties, and commercial real estate and multifamily property appraisals for various investors. Further, it provides appraisal and valuation services; and real estate-related investment banking and advisory services, including housing market research. Additionally, the company offers servicing and asset-managing the portfolio of loans; originates loans through its principal lending and investing activities; and manages third-party capital invested in tax credit equity funds focused on the affordable housing and other commercial real estate sectors. Walker & Dunlop, Inc. was founded in 1937 and is headquartered in Bethesda, Maryland.
Earnings Per Share
As for profitability, Walker & Dunlop has a trailing twelve months EPS of $2.74.
PE Ratio
Walker & Dunlop has a trailing twelve months price to earnings ratio of 35.77. Meaning, the purchaser of the share is investing $35.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 10.4%, now sitting on 972.04M for the twelve trailing months.
Volume
Today’s last reported volume for Walker & Dunlop is 110149 which is 51.76% below its average volume of 228375.
Yearly Top and Bottom Value
Walker & Dunlop’s stock is valued at $98.01 at 01:22 EST, way below its 52-week high of $113.67 and way higher than its 52-week low of $62.51.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 15, 2024, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 2.65%.
5. Hartford Financial Services Group (HIG)
8.5% sales growth and 18.26% return on equity
The Hartford Financial Services Group, Inc., together with its subsidiaries, provides insurance and financial services to individual and business customers in the United States, the United Kingdom, and internationally. Its Commercial Lines segment offers insurance coverages, including workers' compensation, property, automobile, general and professional liability, package business, umbrella, fidelity and surety, marine, livestock, accident, health, and reinsurance through regional offices, branches, sales and policyholder service centers, independent retail agents and brokers, wholesale agents, and reinsurance brokers. The company's Personal Lines segment provides automobile, homeowners, and personal umbrella coverages through direct-to-consumer channels and independent agents. Its Property & Casualty Other Operations segment offers coverage for asbestos and environmental exposures. The company's Group Benefits segment provides group life, disability, and other group coverages to members of employer groups, associations, and affinity groups through direct insurance policies; reinsurance to other insurance companies; employer paid and voluntary product coverages; disability underwriting, administration, and claims processing to self-funded employer plans; and leave management solution. This segment also distributes its group insurance products and services through brokers, consultants, third-party administrators, trade associations, and private exchanges. Its Hartford Funds segment offers managed mutual funds across various asset classes; and exchange-traded funds through broker-dealer organizations, independent financial advisers, defined contribution plans, financial consultants, bank trust groups, and registered investment advisers, as well as investment management, distribution, and administrative services, such as product design, implementation, and oversight. The company was founded in 1810 and is headquartered in Hartford, Connecticut.
Earnings Per Share
As for profitability, Hartford Financial Services Group has a trailing twelve months EPS of $7.97.
PE Ratio
Hartford Financial Services Group has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing $12.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.26%.
Moving Average
Hartford Financial Services Group’s value is below its 50-day moving average of $98.60 and way above its 200-day moving average of $82.45.
Yearly Top and Bottom Value
Hartford Financial Services Group’s stock is valued at $97.78 at 01:22 EST, below its 52-week high of $103.64 and way higher than its 52-week low of $67.42.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 1, 2024, the estimated forward annual dividend rate is 1.88 and the estimated forward annual dividend yield is 1.92%.
6. Jazz Pharmaceuticals plc (JAZZ)
6.6% sales growth and 12.16% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Jazz Pharmaceuticals plc has a trailing twelve months EPS of $6.1.
PE Ratio
Jazz Pharmaceuticals plc has a trailing twelve months price to earnings ratio of 17.94. Meaning, the purchaser of the share is investing $17.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.16%.
Volume
Today’s last reported volume for Jazz Pharmaceuticals plc is 480575 which is 20.07% below its average volume of 601267.
Moving Average
Jazz Pharmaceuticals plc’s value is below its 50-day moving average of $118.38 and way under its 200-day moving average of $125.51.
Yearly Top and Bottom Value
Jazz Pharmaceuticals plc’s stock is valued at $109.46 at 01:22 EST, way below its 52-week high of $146.70 and higher than its 52-week low of $106.61.
Sales Growth
Jazz Pharmaceuticals plc’s sales growth is 6.8% for the present quarter and 6.6% for the next.
7. RCM Technologies (RCMT)
5.3% sales growth and 58.29% return on equity
RCM Technologies, Inc. provides business and technology solutions in the United States, Canada, Puerto Rico, and Serbia. It operates through three segments: Engineering, Specialty Health Care, and Life Sciences and Information Technology. The Engineering segment offers a range of engineering services, including project management engineering and design, engineering analysis, engineer-procure-construct, configuration management, hardware/software validation and verification, quality assurance, technical writing and publications, manufacturing process planning and improvement, and 3D/BIM integrated design. The Specialty Health Care segment provides long-term and short-term staffing, executive search, and placement services in the fields of allied and therapy staffing, correctional healthcare staffing, health information management, nursing services, physician and advanced practice, school services, and telepractice. The Life Sciences and Information Technology segment provides enterprise business solutions, application services, infrastructure solutions, competitive advantage, life sciences solutions, and other vertical market specific solutions. The company serves aerospace and defense, energy, financial services, health care, life sciences, manufacturing and distribution, and technology industries, as well as educational institutions and the public sector. RCM Technologies, Inc. was founded in 1971 and is based in Pennsauken, New Jersey.
Earnings Per Share
As for profitability, RCM Technologies has a trailing twelve months EPS of $1.96.
PE Ratio
RCM Technologies has a trailing twelve months price to earnings ratio of 9.67. Meaning, the purchaser of the share is investing $9.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.29%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 14.6% and 8.5%, respectively.
Moving Average
RCM Technologies’s value is way below its 50-day moving average of $23.22 and way below its 200-day moving average of $23.30.
Previous days news about RCM Technologies(RCMT)
- Why RCM technologies (rcmt) might be well poised for a surge. According to Zacks on Wednesday, 15 May, "Over the past month, one estimate has moved up for RCM Technologies versus no negative revisions. ", "Thanks to promising estimate revisions, RCM Technologies currently carries a Zacks Rank #1 (Strong Buy). "
